Abingdon Health PLC · LSE:ABDX

Abingdon Health — Investor Presentation (January 2024)

9 slides from Abingdon Health's investor presentation, January 2024

  1. Slide 1: Investor Presentation

    Investor Presentation Chris Yates, CEO January 2024

  2. Slide 2: Contents

    Contents 1. Overview 2. Investment Case 3. Trading Statement Highlights 4. Focused Strategy 5. Looking Forward 6. Summary 7. Q&A IMPROVING LIFE BY MAKING RAPID TESTING ACCESSIBLE TO ALL 2

  3. Slide 3: Overview

    Overview WHO WE ARE WHAT WE DO • Founded in 2008, headquartered in York, UK PRODUCTS • Dedicated lateral flow CRO & CDMO • Dedicated lateral flow CRO & CDMO • Offering a range of additional services: regulatory, • 83 employees analytical laboratory service & clinical trial support, packaging design

  4. Slide 4: Investment Case

    Investment Case ● Focused on the Lateral Flow market which is large and growing: o $11.7bn market forecast (2032), 150% increase compared to 2022 o COVID-19 widespread use of lateral flow has reduced barriers to adoption o Technology is simple, cost-effective, easy-to-use o Supports decentralisation

  5. Slide 5: Focused Strategy

    Focused Strategy Lateral Broaden and Self-testing Flow CRO & deepen service lateral flow sales Expand range CDMO offering & distribution and reach 1 2 3 4 • Lateral flow experts • Grow customer base • Range of 14 self-tests under the • Abingdon Simply Test will be • CRO & CDMO service Abingdon Simpl

  6. Slide 6: Trading Update: H1 2023/4

    Trading Update: H1 2023/4 Operational & Financial Highlights Focused Lateral Flow CRO & CDMO service provider H1 Revenue of £2.4m and Revenue Growth of 118% compared to H1 2022/3. Cash of £1.9m. Solid H1 2023/4 with a number of new CDMO projects secured and existing projects progressing well. Select

  7. Slide 7: Looking Forward

    Looking Forward ● Continued growth in CRO and CDMO customer base across contract development, TT, manufacturing & regulatory. ● Over time transition of customers to (long-term) manufacturing customers – Salignostics, LoopDx, UpFront. Others to follow in H2 2023/4. ● Continue to broaden service propo

  8. Slide 8: Summary

    Summary 1 Dedicated lateral flow CRO/CDMO, recognised LFT knowledge leader 2 Lateral flow market large & growing driven by reduced barriers to adoption post-COVID-19 3 Paradigm shift in testing away from lab and into home, clinic, farm or field…. 4 H1 2023/4: 118% like-for-like* revenue growth. Cash

  9. Slide 9: Q&A

    Q&A IMPROVING LIFE BY MAKING RAPID TESTING ACCESSIBLE TO ALL

Abingdon Health — Investor Presentation (January 2024) on 6ix